The European glaucoma prevention study design and baseline description of the participants12 ☆,
Section snippets
Subjects and methods
The European Glaucoma Prevention Study is a multicenter randomized, double-blinded, placebo-controlled clinical trial.
Results
The enrollment of the patients began January 1997 and ran through May 1999. A total of 1081 patients were enrolled. However, because of the enrollment of four patients with glaucoma (protocol violators), the overall number of the randomized patients included in the “intention to treat analysis” was reduced to 1077, which included two patients less than 30 years of age (Table 3). The eligibility criteria were met in 146 patients for the right eye only, in 92 for the left eye only, and in 839
Discussion
Presently, the ophthalmic community often attempts to reduce the IOP of patients with OH using topical medical treatment, with the aim of avoiding the progression to POAG. Clear scientific evidence, however, does not support this common clinical procedure. The three major trials published in the past gave rise to controversial and inconclusive results indicating the need for other trials to address such a relevant clinical issue.9, 10, 11 A more recent study, published by Heijl and Bengtsson,32
Acknowledgements
The EGPS Group thanks the Writing Committee responsible for this article: Stefano Miglior, Thierry Zeyen, Norbert Pfeiffer, Jose Cunha-Vaz, Valter Torri, and Ingrid Adamsons.
References (48)
Glaucomathe damage caused by pressure. XLVI Edward Jackson memorial lecture
Am J Ophthalmol
(1989)- et al.
Vascular risk factors for primary open angle glaucomathe Egna-Neumarkt Study
Ophthalmology
(2000) - et al.
A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects
Ophthalmology
(1989) - et al.
A comparison of treated and untreated glaucoma suspects
Ophthalmology
(1991) Antiglaucoma medicationsa review of safety and tolerability issues related to their use
Clin Ther
(2000)Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors
Prog Retin Eye Res
(2000)Dorzolamidedevelopment and clinical application of a topical carbonic anhydrase inhibitor
Surv Ophthalmol
(1997)Latanoprost. Two years’ experience of its use in the United Kingdom. Latanoprost Study Group
Ophthalmology
(1998)Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost
Am J Ophthalmol
(1997)- et al.
A quantifiable alternative to double data entry
Control Clin Trials
(2000)
Primary open-angle glaucoma, intraocular pressure and systemic blood pressure in the general elderly population. The Rotterdam study
Ophthalmology
The Collaborative Initial Glaucoma Treatment Studystudy design, methods, and baseline characteristics of enrolled patients
Ophthalmology
Early Manifest Glaucoma Trialdesign and baseline data
Ophthalmology
A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients
Ophthalmology
Ocular hypertension and central corneal thickness
Ophthalmology
Relationship between corneal thickness and measured intraocular pressure in a general ophthalmology clinic
Ophthalmology
Prevalence of glaucoma and intraocular pressure distribution in a defined population. The Egna-Neumarkt Study
Ophthalmology
American Academy of Ophthalmology. Primary open-angle glaucoma. Preferred Practice Pattern
Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey
Arch Ophthalmol
Hypertension, perfusion pressure, and primary open angle glaucoma. A population-based assessment
Arch Ophthalmol
Risk factors for open-angle glaucoma. The Barbados Eye Study
Arch Ophthalmol
Family history and risk of primary open angle glaucoma. The Baltimore Eye Survey
Arch Ophthalmol
Elevated intraocular pressure and pseudoexfoliation of the lens capsule as risk factors for chronic open angle glaucoma. A population-based five-year follow-up study
Acta Ophthalmol
Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial
Arch Ophthalmol
Cited by (79)
Risk Calculation in the Medication Arm of the Ocular Hypertension Treatment Study
2023, Ophthalmology GlaucomaLong-term Impact of Immediate Versus Delayed Treatment of Early Glaucoma: Results From the Early Manifest Glaucoma Trial
2023, American Journal of OphthalmologyLaser in Glaucoma and Ocular Hypertension Trial (LIGHT) in China – A Randomized Controlled Trial: Design and Baseline Characteristics
2021, American Journal of OphthalmologyPredictive value of heidelberg retina tomograph parameters for the development of glaucoma in the European glaucoma prevention study
2015, American Journal of OphthalmologyAdvanced imaging for glaucoma study: Design, baseline characteristics, and inter-site comparison
2015, American Journal of OphthalmologyOutcomes
2015, Glaucoma: Second Edition
- ☆
This study is supported by The European Commission (BIOMED II program, contract no.: BMH4-CT-96-1598), and Merck (Whitehouse Station, New Jersey).
- 1
Address correspondence to Stefano Miglior, MD, Universita’ di Milano Bicocca, Ospedale S. Paolo, Via di Rudini’ 8, 20142, Milano, Italy. E-mail: [email protected]
- 2
Reprint requests to Ingrid A. Adamsons, MD, MPH, Merck Research Laboratories, 10 Sentry Parkway, BL1-3, Blue Bell, PA 19422.